Search Results Search Sort by RelevanceMost Recent Medicine and Society Jul 2021 How Pharmaceuticals Mask Health and Social Inequity Enrico G. Castillo, MD, MSHPM and Joel Tupper Braslow, MD, PhD Pharmaceuticals make symptoms and biological drug targets more visible but can render individual and community suffering less visible. AMA J Ethics. 2021;23(7):E542-549. doi: 10.1001/amajethics.2021.542. Policy Forum Aug 2019 Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications? Jordan M. Warchol, MD, MPH In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013. AMA J Ethics. 2019;21(8):E661-667. doi: 10.1001/amajethics.2019.661. Viewpoint May 2022 Reimagining Roles of Dietary Supplements in Psychiatric Care Katherine Wu, MD and Erik Messamore, MD, PhD Government-supported review and safety monitoring is needed for dietary supplements’ use in the care of patients with mental illness. AMA J Ethics. 2022;24(5):E437-442. doi: 10.1001/amajethics.2022.437. Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777. History of Medicine May 2024 A Brief History of Antimicrobial Resistance Devin Hunt and Olivia S. Kates, MD, MA Resistance has dogged infectious disease treatment processes since we started using modern antimicrobials. AMA J Ethics. 2024;26(5):E408-417. doi: 10.1001/amajethics.2024.408.
Medicine and Society Jul 2021 How Pharmaceuticals Mask Health and Social Inequity Enrico G. Castillo, MD, MSHPM and Joel Tupper Braslow, MD, PhD Pharmaceuticals make symptoms and biological drug targets more visible but can render individual and community suffering less visible. AMA J Ethics. 2021;23(7):E542-549. doi: 10.1001/amajethics.2021.542.
Policy Forum Aug 2019 Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications? Jordan M. Warchol, MD, MPH In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013. AMA J Ethics. 2019;21(8):E661-667. doi: 10.1001/amajethics.2019.661.
Viewpoint May 2022 Reimagining Roles of Dietary Supplements in Psychiatric Care Katherine Wu, MD and Erik Messamore, MD, PhD Government-supported review and safety monitoring is needed for dietary supplements’ use in the care of patients with mental illness. AMA J Ethics. 2022;24(5):E437-442. doi: 10.1001/amajethics.2022.437.
Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.
History of Medicine May 2024 A Brief History of Antimicrobial Resistance Devin Hunt and Olivia S. Kates, MD, MA Resistance has dogged infectious disease treatment processes since we started using modern antimicrobials. AMA J Ethics. 2024;26(5):E408-417. doi: 10.1001/amajethics.2024.408.